Floatz logo

FLUOROURACILUM

Consolidation Therapy

Seoul National University HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

10 Active assets in the Consolidation Therapy cohort.

Asset / SponsorPhaseRating
Pyrotinib
Sun Yat-sen University
Phase 2CCC
Tislelizumab
Sun Yat-sen University
Phase 2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Sun Yat-sen University
Phase 2CCC
Venetoclax
The First Affiliated Hospital of Soochow University
Phase 2CCC
Azacitidine
The First Affiliated Hospital of Soochow University
Phase 2CCC

View all 10 →

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →